IMVT

Van Tuyl Christopher

Known title: Chief Legal OfficerCIK: 0001779707

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.

this person other insiders at IMVT

Transaction History

IMVT▼ Sell$43K
IMVT▼ Sell$103K
IMVT▼ Sell$45K
IMVT▼ Sell$3K
IMVT▼ Sell$111K
IMVT▲ Buy$271K
IMVT▼ Sell$572K
IMVT▼ Sell$93K
IMVT▼ Sell$128K
IMVT▲ Buy$0
IMVT▼ Sell$72K
IMVT▼ Sell$228K
IMVT▼ Sell$63K
IMVT▲ Buy$0
IMVT▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.